



National Peroxide Limited

CIN : L24299MH1954PLC009254



RESPONSIBLE CARE®
OUR COMMITMENT TO SUSTAINABILITY

REGISTERED OFFICE : NEVILLE HOUSE, J. N. HEREDIA MARG, BALLARD ESTATE, MUMBAI - 400 001.

February 14, 2023

BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001.

Kind Attn: Dept. of Corporate Services
(Scrip Code – 500298)

Dear Sir / Madam,

Sub: Outcome of Board Meeting

Ref: Submission of Unaudited Financial Results for the Quarter and Nine Months ended December 31, 2022 as per Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

This is to inform you that the Board of Directors of National Peroxide Limited (“the Company”) at their meeting held today i.e., February 14, 2023, have considered and approved the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2022.

The Unaudited Standalone and Consolidated Financial Results of the Company and the Limited Review Reports for the quarter and nine months ended December 31, 2022 are enclosed.

The meeting of the Board of Directors commenced at 11:15 a.m. and concluded at 01:05 p.m.

Kindly take said information on record.

Yours faithfully,
For National Peroxide Limited

CS Heena Shah
Company Secretary and Compliance Officer

Encl.: as above

Correspondence to be addressed to :

Head Office : C-1, Wadia International Centre, Pandurang Budhkar Marg, Worli, Mumbai - 400 025.

Tel. : +91-22-66620000 • Fax : +91-22-24314709 • E-mail : npl@naperol.com • Website : www.naperol.com

KALYANIWALLA & MISTRY LLP

CHARTERED ACCOUNTANTS

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of National Peroxide Limited pursuant to Regulation 33 of the Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

**Review Report to
The Board of Directors,
National Peroxide Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of **National Peroxide Limited** ("the Company"), for the quarter ended December 31, 2022 and the year to date results for the period from April 01, 2022 to December 31, 2022, together with the notes thereon ("the Statement") attached herewith. The Statement is being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations") (initialled by us for identification).
2. The Statement, which is the responsibility of the Company's Management has been reviewed by the Audit Committee and approved by the Company's Board of Directors at their meetings held on February 13, 2023 and February 14, 2023, respectively. The Statement has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, ("the Act") read with the relevant Rules issued thereunder, as applicable and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SREs) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



LLP IN : AAH - 3437

REGISTERED OFFICE : ESPLANADE HOUSE, 29, HAZARIMAL SOMANI MARG, FORT, MUMBAI 400 001
TEL.: (91) (22) 6158 6200, 6158 7200 FAX: (91) (22) 6158 6275

**KALYANIWALLA
& MISTRY LLP**

5. Attention is drawn to the fact that the comparative financial information of the Company for the quarter ended June 30, 2022 and for the periods upto year ended March 31, 2022 included in the Statement have been reviewed / audited by the predecessor auditor. The reports of the predecessor auditor on comparative financial information referred to in this paragraph, expressed an unmodified conclusion / opinion, which have been furnished to us and have been relied upon by us for the purpose of our review of the Statement.

Our conclusion on the Statement is not modified in respect of the above matter.

For **KALYANIWALLA & MISTRY LLP**
CHARTERED ACCOUNTANTS
Firm Reg. No. 104607W / W100166



Jamshed K. Udawadia

Partner

Membership No.: 124658

UDIN: 23124658BGXLJN7840

Mumbai

February 14, 2023



NATIONAL PEROXIDE LIMITED

Registered Office : Neville House, J.N.Heredia Marg, Ballard Estate, Mumbai - 400 001
CIN : L24299MH1954PLC009254

Tel No: (022) 66620000 • Website: www.naperol.com • E-mail: secretarial@naperol.com

(₹ in Lakhs)

Statement of Unaudited Standalone Financial Results for the Quarter and Nine Months Ended December 31, 2022

Sr. No	Particulars	Quarter ended			Nine Months ended		Year ended
		December 31, 2022	September 30, 2022	December 31, 2021	December 31, 2022	December 31, 2021	March 31, 2022
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I	Income						
	(a) Revenue from Operations	11,511.50	9,667.02	7,973.67	28,757.10	17,545.63	22,540.74
	(b) Other Income	345.30	316.11	126.54	827.67	841.41	1,021.26
II	Total Income	11,856.80	9,983.13	8,100.21	29,584.77	18,387.04	23,562.00
III	Expenses						
	(a) Cost of Raw Materials and Packing Materials Consumed	4,326.68	5,328.02	3,905.48	14,409.90	8,327.53	10,317.22
	(b) Purchase of stock in trade	115.38	16.01	-	131.39	228.79	410.09
	(c) Changes in Inventories of Stock in Trade and Finished Goods	541.92	91.82	(448.70)	(491.30)	(335.73)	208.72
	(d) Power, Fuel and Water	1,302.55	1,520.06	1,067.69	4,190.14	2,676.44	3,326.97
	(e) Employee Benefits Expense	763.50	617.11	673.29	2,023.52	2,063.30	2,698.39
	(f) Finance Costs	152.69	170.06	207.89	504.09	687.66	883.36
	(g) Depreciation and Amortisation Expense	562.17	457.24	444.14	1,463.92	1,307.37	1,743.65
	(h) Other Expenses	1,757.31	1,449.30	1,035.48	4,736.99	2,723.83	3,929.26
	Total Expenses (III)	9,522.20	9,649.62	6,885.27	26,968.65	17,679.19	23,517.66
IV	Profit before Exceptional Items and Tax (II - III)	2,334.60	333.51	1,214.94	2,616.12	707.85	44.34
V	Exceptional Income (Refer Note 4)	-	-	-	1,590.79	-	700.00
VI	Profit before Tax (IV + V)	2,334.60	333.51	1,214.94	4,206.91	707.85	744.34
VII	Tax Expenses						
	(a) Current tax	419.12	43.06	55.68	489.17	55.68	-
	(b) Deferred tax	175.91	20.87	275.92	562.39	142.40	235.73
VIII	Profit after Tax for the period (VI - VII)	1,739.57	269.58	883.34	3,155.35	509.77	508.61
IX	Other Comprehensive Income						
	(a) Items that will not be reclassified to profit or loss	(441.45)	319.43	(641.15)	817.88	600.70	(5,292.71)
	(b) Income tax relating to items that will not be reclassified to profit or loss	9.60	(20.58)	40.11	(12.98)	(7.46)	240.83
	(c) Items that will be reclassified to profit or loss	9.93	36.58	68.39	70.39	94.70	192.85
	(d) Income tax relating to items that will be reclassified to profit or loss	(2.50)	(9.21)	(17.21)	(17.72)	(23.83)	(48.54)
	Total Other Comprehensive Income / (Loss). Net of Income Tax (IX)	(424.42)	326.22	(549.86)	857.57	664.11	(4,907.57)
X	Total Comprehensive income / (Loss) for the period (VIII + IX)	1,315.15	595.80	333.48	4,012.92	1,173.88	(4,398.96)
XI	Paid up Equity Share Capital (Face value of ₹ 10/- each)	574.70	574.70	574.70	574.70	574.70	574.70
XII	Reserves excluding Revaluation Reserves as per previous accounting year (Other Equity)						53,149.62
XIII	Earnings per Equity Share (Face value of ₹ 10/- each) *						
	(1) Basic (In ₹.)	30.27	4.69	15.37	54.90	8.87	8.85
	(2) Diluted (In ₹.)	30.27	4.69	15.37	54.90	0.07	0.05

* Basic and Diluted EPS for all periods, except year ended 31.03.2022, are not annualised

- The above results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meetings held on February 13, 2023 and February 14, 2023 respectively. The statutory auditors have carried out a limited review of the results for the quarter and nine months ended December 31, 2022.
- This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules, issued thereunder and other recognised accounting practices and policies to the extent applicable.
- The Company's business segment consists of a single segment of "Manufacturing of Hydrogen Peroxide" as per Indian Accounting Standard (Ind AS-108) Operating Segments requirement.
- The Exceptional Items for the quarter and nine months ended December 31, 2022 represent following items:

Particulars	Quarter ended			Nine Months ended		Year ended
	December 31, 2022	September 30, 2022	December 31, 2021	December 31, 2022	December 31, 2021	March 31, 2022
	(₹ in Lakhs)	(₹ in Lakhs)	(₹ in Lakhs)	(₹ in Lakhs)	(₹ in Lakhs)	(₹ in Lakhs)
Insurance claim received due to loss on account of breakdown of machinery (Refer Note a)	-	-	-	1,295.16	-	250.00
Compensation for Right of Way on the Company's property (Net) (Refer Note b)	-	-	-	295.63	-	450.00
Total	-	-	-	1,590.79	-	700.00

(a) The Company received insurance claim towards the machinery breakdown incident that occurred in March 2021 which was settled by the insurance company at the replacement value for Rs. 1,545.16 lakhs, against which an amount of Rs. 250.00 lakhs was received during the quarter ended March 31, 2022 and the balance amount of Rs. 1,295.16 lakhs was received during the quarter ended June 30, 2022.

(b) During the quarter ended March 31, 2022 and June 30, 2022, the Company received net compensation of Rs. 450.00 lakhs and Rs. 295.63 lakhs respectively, as per the terms of the out-of-court settlement agreed between the Company and Century Rayon Limited towards Right of Way for laying of 100 KV Extra High Voltage (EHV) transmission line and EHV towers on the land of the Company.

- The Composite Scheme of Arrangement filed with the Hon'ble National Company Law Tribunal, Mumbai Bench ("NCLT") was amended by the Board of Directors of the Company at its meeting held on September 20, 2022, which inter-alia amended (i) change in Appointed Date from October 1, 2020 to April 1, 2022; and (ii) include provisions in relation to lease of land by National Peroxide Limited to NPL Chemicals Limited.

The Scheme is subject to approval of the Hon'ble NCLT and such other statutory and regulatory authorities as may be required.

- Previous year/ period figures have been re-grouped / re-classified wherever necessary.

For National Peroxide Limited



Rajiv Arora
Chief Executive Officer and Director
DIN: 08730235
Place : Mumbai
Date: February 14, 2023



KALYANIWALLA & MISTRY LLP

CHARTERED ACCOUNTANTS

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of National Peroxide Limited pursuant to Regulation 33 of the Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

**Review Report to
The Board of Directors,
National Peroxide Limited**

1. We have reviewed the accompanying statement of unaudited consolidated financial results of **National Peroxide Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended December 31, 2022 and the year to date results for the period from April 01, 2022 to December 31, 2022, together with the notes thereon ("the Statement") attached herewith. The Statement is being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations") (initialled by us for identification).
2. The Statement, which is the responsibility of the Parent's Management has been reviewed by the Parent's Audit Committee and approved by the Parent's Board of Directors at their meetings held on February 13, 2023 and February 14, 2023, respectively. The Statement has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 ("the Act"), read with relevant Rules issued thereunder, as applicable and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SREs) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.



LLP IN : AAH - 3437

REGISTERED OFFICE : ESPLANADE HOUSE, 29, HAZARIMAL SOMANI MARG, FORT, MUMBAI 400 001
TEL.: (91) (22) 6158 6200, 6158 7200 FAX : (91) (22) 6158 6275

4. The Statement includes the financial results of the following entities:

Name of the Entity	Relationship
National Peroxide Limited	Parent Company
Naperol Investments Limited	Subsidiary Company
NPL Chemicals Limited	Subsidiary Company

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review report of the other auditor referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Ind AS and other recognised accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial results of a subsidiary, included in the Statement, whose interim financial results reflect total revenues (before consolidation adjustments) of Rs. 3.62 lakhs, and Rs. 57.55 lakhs for the quarter and nine months ended December 31, 2022 respectively, total net profit after tax (before consolidation adjustments) of Rs. 0.22 lakhs and Rs. 36.04 lakhs for the quarter and nine months ended December 31, 2022 respectively, total comprehensive income (loss) (before consolidation adjustments) of Rs. (457.51) lakhs and Rs. 1937.87 lakhs for the quarter and nine months ended December 31, 2022 respectively, as considered in the Statement. These interim financial results have been reviewed by other auditor whose limited review report has been furnished to us by the Parent's Management, and our conclusion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based on the report of such other auditor and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matter.

7. We did not review the interim financial results of a subsidiary, included in the Statement, whose interim financial results reflect total revenues (before consolidation adjustments) of Rs. Nil, both for the quarter and nine months ended December 31, 2022, total net (loss) after tax (before consolidation adjustments) of Rs. (0.27) lakhs and Rs. (1.16) lakhs for the quarter and nine months ended December 31, 2022 respectively, total comprehensive (loss) (before consolidation adjustments) of Rs. (0.27) lakhs and Rs. (1.16) lakhs for the quarter and nine months ended December 31, 2022 respectively, as considered in the Statement. These interim financial results have been certified and furnished to us by the Parent's Management, and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary and to the extent, has been derived from such management certified financial results. According to the information and explanations given to us by the Parent's Management, these financial results are not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matter.



8. Attention is drawn to the fact that the comparative financial information of the Group for the quarter ended June 30, 2022 and for the periods upto year ended March 31, 2022 included in the Statement have been reviewed / audited by the predecessor auditor. The reports of the predecessor auditor on comparative financial information referred to in this paragraph, expressed an unmodified conclusion / opinion, which have been furnished to us and have been relied upon by us for the purpose of our review of the Statement.

Our conclusion on the Statement is not modified in respect of the above matter.

For KALYANIWALLA & MISTRY LLP
CHARTERED ACCOUNTANTS
Firm Reg. No. 104607W / W100166



Jamshed K. Udawadia

Partner

Membership No.: 124658

UDIN: 23124658BGXLT07711

Mumbai

February 14, 2023



(₹ in Lakhs)

Statement of Unaudited Consolidated Financial Results for the Quarter and Nine Months Ended December 31, 2022

Sr. No	Particulars	Quarter ended			Nine months ended		Year ended
		December 31, 2022	September 30, 2022	December 31, 2021	December 31, 2022	December 31, 2021	March 31, 2022
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I	Income						
	(a) Revenue from Operations	11,515.12	9,719.84	7,974.24	28,814.65	17,598.09	22,594.07
	(b) Other Income	345.23	316.11	126.54	827.60	841.41	1,021.26
II	Total Income	11,860.35	10,035.95	8,100.78	29,642.25	18,439.50	23,615.33
III	Expenses						
	(a) Cost of Raw Materials and Packing Materials Consumed	4,326.68	5,328.02	3,905.48	14,409.90	8,327.53	10,317.22
	(b) Purchase of stock in trade	115.38	16.01	-	131.39	228.79	410.09
	(c) Changes in Inventories of Stock in Trade and Finished Goods	541.92	91.82	(448.70)	(491.30)	(335.73)	208.72
	(d) Power, Fuel and Water	1,302.55	1,520.06	1,067.69	4,190.14	2,676.44	3,326.97
	(e) Employee Benefits Expense	763.50	617.11	673.29	2,023.52	2,063.30	2,698.39
	(f) Finance Costs	152.69	170.06	207.89	504.09	687.66	883.36
	(g) Depreciation and Amortisation Expense	562.17	457.24	444.14	1,463.92	1,307.37	1,743.65
	(h) Other Expenses	1,761.29	1,449.86	1,035.69	4,747.93	2,725.16	3,932.10
	Total Expenses (III)	9,526.18	9,650.18	6,885.48	26,979.59	17,680.52	23,520.50
IV	Profit before Exceptional Items and Tax (II - III)	2,334.17	385.77	1,215.30	2,662.66	758.98	94.83
V	Exceptional Income (Refer Note 5)	-	-	-	1,590.79	-	700.00
VI	Profit before Tax (IV + V)	2,334.17	385.77	1,215.30	4,253.45	758.98	794.83
VII	Tax Expenses						
	(a) Current tax	418.20	54.55	55.67	499.74	68.39	15.78
	(b) Deferred tax	176.45	21.19	276.02	563.48	142.59	236.07
VIII	Profit after Tax for the period (VI - VII)	1,739.52	310.03	883.61	3,190.23	548.00	542.98
IX	Other Comprehensive Income						
	(a) Items that will not be reclassified to profit or loss	(899.25)	874.69	(2,213.05)	2,719.65	730.66	(15,840.79)
	(b) Income tax relating to items that will not be reclassified to profit or loss	9.68	(20.61)	42.70	(12.91)	(8.42)	255.46
	(c) Items that will be reclassified to profit or loss	9.93	36.58	68.39	70.39	94.70	192.85
	(d) Income tax relating to items that will be reclassified to profit or loss	(2.50)	(9.21)	(17.21)	(17.72)	(23.83)	(48.54)
	Total Other Comprehensive Income / (Loss), Net of Income Tax (IX)	(882.14)	881.45	(2,119.17)	2,759.41	793.11	(15,441.02)
X	Total Comprehensive Income / (Loss) for the period (VIII + IX)	857.38	1,191.48	(1,235.56)	5,949.64	1,341.11	(14,898.04)
XI	Paid up Equity Share Capital (Face value of ₹ 10/- each)	574.70	574.70	574.70	574.70	574.70	574.70
XII	Reserves excluding Revaluation Reserves as per previous accounting year (Other Equity)						90,485.50
XIII	Profit attributable to:						
	Owners of the Company	1,739.52	310.03	883.61	3,190.23	548.00	542.98
	Non-controlling interest	-	-	-	-	-	-
	Other comprehensive income attributable to:						
	Owners of the Company	(882.14)	881.45	(2,119.17)	2,759.41	793.11	(15,441.02)
	Non-controlling interest	-	-	-	-	-	-
	Total comprehensive Income attributable to	857.38	1,191.48	(1,235.56)	5,949.64	1,341.11	(14,898.04)
	Owners of the Company	857.38	1,191.48	(1,235.56)	5,949.64	1,341.11	(14,898.04)
	Non-controlling interest	-	-	-	-	-	-
XIV	Earnings per Equity Share (Face value of ₹ 10/- each) *						
	(1) Basic (In ₹.)	30.27	5.39	15.38	55.51	9.54	9.45
	(2) Diluted (In ₹.)	30.27	5.39	15.38	55.51	9.54	9.45

* Basic and Diluted EPS for all periods, except year ended 31.03.2022, are not annualised

- The Statement of Unaudited Consolidated Financial Results includes results of National Peroxide Limited (the "Parent Company") and its subsidiaries (Collectively referred as the "Group")
- The above results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meetings held on February 13, 2023 and February 14, 2023 respectively. The statutory auditors have carried out a limited review of the results for the quarter and nine months ended December 31, 2022.
- This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- The Group's business segment consists of a single segment of "Manufacturing of Hydrogen Peroxide" as per Indian Accounting Standard (Ind AS-108) Operating Segments requirement.
- The Exceptional Items for the quarter and nine months ended December 31, 2022 represent following items: (₹ in Lakhs)

Particulars	Quarter ended			Nine Months ended		Year ended
	December 31, 2022	September 30, 2022	December 31, 2021	December 31, 2022	December 31, 2021	March 31, 2022
Insurance claim received due to loss on account of breakdown of machinery (Refer Note a)	-	-	-	1,295.16	-	250.00
Compensation for Right of Way on the Group's property (Net) (Refer Note b)	-	-	-	295.63	-	450.00
Total	-	-	-	1,590.79	-	700.00

(a) The Group received insurance claim towards the machinery breakdown incident that occurred in March 2021 which was settled by the insurance company at the replacement value for Rs. 1,545.16 lakhs, against which an amount of Rs. 250.00 lakhs was received during the quarter ended March 31, 2022 and the balance amount of Rs. 1,295.16 lakhs was received during the quarter ended June 30, 2022.

(b) During the quarter ended March 31, 2022 and June 30, 2022, the Group received net compensation of Rs. 450.00 lakhs and Rs. 295.63 lakhs respectively, as per the terms of the out-of-court settlement agreed between the Parent Company and Century Rayon Limited towards Right of Way for laying of 100 KV Extra High Voltage (EHV) transmission line and EHV towers on the land of the Parent Company.

- The Composite Scheme of Arrangement filed with the Hon'ble National Company Law Tribunal, Mumbai Bench ("NCLT") was amended by the Board of Directors of the Parent Company at its meeting held on September 20, 2022, which inter-alia amended (i) change in Appointed Date from October 1, 2020 to April 1, 2022; and (ii) include provisions in relation to lease of land by National Peroxide Limited to NPL Chemicals Limited.

The Scheme is subject to approval of the Hon'ble NCLT and such other statutory and regulatory authorities as may be required.

- Previous period figures have been re-grouped / re-classified wherever necessary.

For National Peroxide Limited



Rajiv Arora
Chief Executive Officer and Director
DIN: 08730235
Place : Mumbai
Date: February 14, 2023

